Format

Send to

Choose Destination
Br J Cancer. 2018 Dec;119(12):1464-1470. doi: 10.1038/s41416-018-0293-5. Epub 2018 Nov 23.

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.

Author information

1
Cancer Institute, University Hospital Fundación Jiménez Díaz, Autonomous University of Madrid, Madrid, Spain. jgfoncillas@gmail.com.
2
Medical Oncology Department, Vall d'Hebron Institute of Oncology (CIBERONC), Barcelona, Spain.
3
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
4
Medical Oncology Department, Reina Sofía University Hospital (UCO, IMIBIC, CIBERONC), Córdoba, Spain.
5
Medical Oncology Department, Virgen de la Victoria University Hospital, Malaga, Spain.
6
Medical Oncology Department, General University Hospital of Valencia, Valencia, Spain.
7
Department of Medicine, Universitat de Valencia (CIBERONC), Valencia, Spain.
8
Molecular Oncology Laboratory, General University Hospital Research Foundation, Valencia, Spain.
9
Department of Biotechnology, Universitat Politècnica de València (CIBERONC), Valencia, Spain.
10
Traslational Medical Oncology Group/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), University Hospital of Santiago de Compostela (CIBERONC), Santiago, Spain.
11
Dept. of Medical Oncology, Hospital del Mar (IMIM, CIBERONC), Barcelona, Spain.
12
Medical Oncology Department, Miguel Servet University Hospital-ISS Aragon (CIBERONC), Zaragoza, Spain.
13
Department of Medical Oncology, Cruces University Hospital, Barakaldo, Spain.
14
Department of Medical Oncology, San Carlos Clinic Hospital (CIBERONC, IdISCC), Madrid, Spain.
15
Pathology Department, IIS-Fundación Jimenez Diaz (CIBERONC), Madrid, Spain.
16
Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Abstract

BACKGROUND:

Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented.

METHODS:

Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient.

RESULTS:

The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689-0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease.

CONCLUSIONS:

In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy.

PMID:
30467411
PMCID:
PMC6288144
DOI:
10.1038/s41416-018-0293-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center